Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy-Reference-Cited by-同舟云学术

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy

Published:2020-01 Issue:1 Volume:26 Page:34-43
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Ruark Julia,Mullane Erin,Cleary Nancy,Cordeiro Ana,Bezerra Evandro D.,Wu Vicky,Voutsinas Jenna,Shaw Bronwen E.,Flynn Kathryn E.^ORCID,Lee Stephanie J.,Turtle Cameron J.,Maloney David G.,Fann Jesse R.,Bar Merav

Funder

National Institutes of Health

National Cancer Institute

National Institute of Diabetes and Digestive and Kidney Diseases

National Heart, Lung, and Blood Institute

Indiana University

Celgene

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference59 articles.

1. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N Engl J Med,2018

2. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

3. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

4. Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation;Kansagra;Biol Blood Marrow Transplant,2019

5. Utilization of chimeric antigen receptor (CAR) T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy;Jain;Biol Blood Marrow Transplant,2019

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cognitive Symptoms Across Diverse Cancers;JAMA Network Open;2024-08-28

2. Survivorship preparedness and activation among survivors of lymphoma;Journal of Cancer Survivorship;2024-08-27

3. Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy;BMC Cancer;2024-08-09

4. Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T‐cell therapy in pediatrics;Pediatric Blood & Cancer;2024-06-12

5. Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma;Frontiers in Oncology;2024-06-11